BRCA1 and neoplasm: Increased cytotoxicity and anti-tumor activity were observed in cell lines and mice tumor models with defects in BRCA1/2, ATM, or other genes involved in DNA repair after treatment with olaparib, and this was linked with platinum responsiveness [19,20].